Unknown

Dataset Information

0

Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.


ABSTRACT: Increases in ?-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that ?2-adrenergic receptor (?2AR) agonists decrease histone acetylation in the ?-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with ?2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.

SUBMITTER: Abdelmotilib H 

PROVIDER: S-EPMC5649055 | biostudies-other | 2017 Oct

REPOSITORIES: biostudies-other

altmetric image

Publications

Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.

Abdelmotilib Hisham H   West Andrew B AB  

Genome medicine 20171019 1


Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease. ...[more]

Similar Datasets

| S-EPMC5822406 | biostudies-literature
| S-EPMC5964193 | biostudies-literature
| S-EPMC5830552 | biostudies-literature
| S-EPMC7613924 | biostudies-literature
| S-EPMC9731568 | biostudies-literature
| S-EPMC10435076 | biostudies-literature
| S-EPMC3909978 | biostudies-literature
| S-EPMC4760087 | biostudies-literature
| S-EPMC9369449 | biostudies-literature
| S-EPMC4034002 | biostudies-literature